The Court of Appeal partially reversed the Brussels Commercial Court’s decision invalidating Lundbeck’s SPC for escitalopram, to the extent that it had immediate effect.
A summary of this case will be posted on http://www.KluwerIPCases.com
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
Kluwer IP Law
The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?
Learn how Kluwer IP Law can support you.